Johnson & Johnson will present 12-month interim results from its VARIPURE study at the 2026 PFA Summit. The company scheduled the data presentation for April 11. This study evaluates the Varipulse platform for pulsed field ablation (PFA) to treat heart rhythm disorders.
The presentation follows the European launch of Varipulse Pro after receiving CE-mark approval. The updated platform features a new pulse sequence designed to be five times faster than previous iterations.
The technology aims to improve procedural efficiency while maintaining a strong safety profile. Johnson & Johnson will also showcase the Varipulse Pro platform at the European Heart Rhythm Association (EHRA) annual meeting.